Brief: Beam Therapeutics Announces First Patient Dosed In The Phase 1/2 Study Of Beam-302
26/06/2024 11:34
June 26 (Reuters) - Beam Therapeutics Inc BEAM.O :
* BEAM THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
PHASE 1/2
STUDY OF BEAM-302 IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Source text for Eikon: ID:nGNX6p1XZk
Further company coverage: BEAM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta